RxDoctor Payments Data

Eduardo Ramirez de Arellano Gonzalez, MD

Internal Medicine · Winter Haven, FLNPI 1326408477

Payments from drug & device makers

$4,602in general payments, 2019–2025

Across 189 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$390
  • Novo Nordisk$353
  • Bayer$338
  • GSK$293
  • Merck$291
  • Dexcom, Inc.$276
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$4,56099%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,602 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$132,499
Medicare patients
195
Services billed
4,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$110,275
EliquisApixaban44$62,379
LinzessLinaclotide49$43,831
XareltoRivaroxaban25$35,737
JardianceEmpagliflozin22$34,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$31,801
FarxigaDapagliflozin Propanediol22$27,828
Nucynta ErTapentadol Hcl13$23,019
MounjaroTirzepatide15$15,764
Humalog Kwikpen U-200Insulin Lispro16$14,778
Repatha SureclickEvolocumab15$12,699
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,813
Wixela InhubFluticasone Propion/Salmeterol36$2,990
Pregabalin104$2,637
Atorvastatin Calcium225$2,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$353$111,71598 claims
PfizerEliquis$390$62,37944 claims
AbbVieLinzess, Synthroid$203$46,04168 claims
Johnson & JohnsonXarelto$106$35,73725 claims
Boehringer IngelheimJardiance$262$34,50722 claims
GSKTrelegy Ellipta$293$31,80149 claims
AstraZenecaFarxiga$264$27,82822 claims
Lilly USA, LLCMounjaro$250$15,76415 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$1,137121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →